Completed PHASE2 INTERVENTIONAL 2-arm NCT00204308

Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP (TD-2)

Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission

Sponsor: Elizabeth Glaser Pediatric AIDS Foundation

Conditions HIV Pregnancy

Interventions Combination tenofovir-emtricitabine

Updated 6 times since 2017 Last updated: May 30, 2012 Started: Mar 31, 2005 Primary completion: May 31, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00204308, this PHASE2 trial focuses on HIV and Pregnancy and remains completed. Sponsored by Elizabeth Glaser Pediatric AIDS Foundation, it has been updated 6 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Elizabeth Glaser Pediatric AIDS Foundation
University of North Carolina, Chapel Hill

Data source: University of North Carolina, Chapel Hill

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lusaka, Zambia